Pricing

CORMORANT ASSET MANAGEMENT, LP

7 followers · 1 like
BOSTON MA Investment Advisor Hedge Fund
13F Summary

Subscription Required

Equal-WT
WhaleScore 2.0 ?

85

S&P 500
WhaleScore ?

Subscription Required

Equal-WT
WhaleScore 1.0 ?

Cormorant Asset Management is based out of Boston. Cormorant Asset Management is a hedge fund with 14 clients and discretionary assets under management (AUM) of $4,022,479,936 (Form ADV from 2024-03-30). Their last reported 13F filing for Q1 2024 included $2,279,648,201 in managed 13F securities and a top 10 holdings concentration of 55.42%. Cormorant Asset Management's largest holding is MoonLake Immunotherapeutics with shares held of 8,494,151. Whalewisdom has at least 43 13F filings, 4 13D filings, 233 13G filings, and 79 Form 4 filings

2024-03-31

Top Buys (13F)

2024-03-31

Top Sells (13F)

Name % Change
AMAM Ambrx Biopharma Inc. 7.64%
RYZB RayzeBio Inc. 3.6%
IMVT Immunovant Inc 2.34%
BBIO BridgeBio Pharma Inc 2.1%
CBAY Cymabay Therapeutics 2.03%

2024-03-31

13F Holdings Summary

Name $ Change
MLTX MoonLake Immunothera 18.72%
EYPT EYEPOINT PHARMACEUTI 6.25%
ACLX Arcellx Inc 5.43%
ALPN Alpine Immune Scienc 4.69%
BBIO BridgeBio Pharma Inc 4.34%

2024-03-31

13F Activity

Market Value $2.28b, Prior: $2.09b
Inflows (Outflows) as % of Total MV +1.3896%
New Purchases 19 stocks
Added To 9 stocks
Sold out of 10 stocks
Reduced holdings in 10 stocks
Top 10 Holdings % 55.42%
Turnover %[1] 43.28%
Turnover Alt %[2] 21.46%
Time Held Top 20 2.15 quarters
Time Held Top 10 1.8 quarters
Time Held All 5.89 quarters

[1]: Turnover is calculated by taking the # of new holdings (initial purchases) + the # of positions sold out of (not just reduced) divided by the total # of holdings for the quarter.

[2]: Alt Turnover is calculated by taking either the total MV of new purchases or the MV of securities sold, whichever is less, divided by the total MV of the fund.

2024-03-31

13F Sector Allocation Over Time

2024-03-31

Analysis

Top 20 equal-weighted holdings. Performance numbers calculated through 2024-03-31

Portfolio Performance